Physician profile
Barbara Schechter
NPI 1427440932
$7,507.94
in general payments reported to CMS, 2019-2025
17 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $152 · 2021: $722 · 2022: $410 · 2023: $2,152 · 2024: $1,803 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,086 · Food and Beverage: $2,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,086.04 |
| Food and Beverage | $2,253.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,991.84 | 2019-2025 | Mitraclip, Merlin@Home |
| Edwards Lifesciences Corporation | $672.93 | 2019-2025 | Evoque, Pascal |
| Boston Scientific Corporation | $418.03 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $279.71 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $266.42 | 2023-2025 | Wainua, Andexxa |
| Novartis Pharmaceuticals Corporation | $259.60 | 2022-2025 | |
| Kestra Medical Technology Services, INC. | $187.14 | 2024-2025 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $147.14 | 2025 | Amvuttra |
| Medtronic, INC. | $64.04 | 2021 | |
| Abiomed | $46.93 | 2024 | Impella |
| Pfizer INC. | $45.04 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $33.25 | 2024 | Arcalyst |
| Novo Nordisk INC | $25.10 | 2025 | Wegovy |
| Heartflow, INC. | $24.00 | 2025 | |
| Esperion Therapeutics, INC. | $16.47 | 2024 | Nexletol |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2025 | Camzyos |
| Amgen INC. | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Schechter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.